Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening
Have a BMI of ≥27 kg/m2 at screening
Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight
You may not be if
Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes
Have taken any of the following within 90 days prior to screening
* medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies
* dipeptidyl peptidase 4 (DPP-4) inhibitors, and
* insulin
Have had within 90 days prior to screening:
* heart attack
* stroke
* coronary artery revascularization
* unstable angina, or
* hospitalization due to congestive heart failure
Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
Have taken medications or alternative remedies intended for weight loss within 90 days of screening
Clareo Health | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
